GSK will spin off its consumer health business Haleon worth up to an estimated £48bn on Monday in the biggest listing in Europe in over a decade.
Read the full article on the Reuters website
NAM Implications:
- Haleon is poised to generate above-market, medium-term annual organic revenue growth of 4% to 6%.
- i.e. Stock market pressure to excel…
- …which, added to GSK ability to focus 100% on Haleon..
- …makes for a formidable (Enterprise value of £33bn to £48bn) player in these categories.
